{"id":"W3098262983","doi":"10.1093/noajnl/vdaa124","title":"Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02","year":2020,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Sorafenib; Erlotinib; Medicine; Clinical endpoint; Oncology; Internal medicine; Pharmacokinetics; Pharmacology; Phases of clinical research; Tyrosine-kinase inhibitor; Clinical trial; Epidermal growth factor receptor; Hepatocellular carcinoma; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004170664,0.002740512,0.002912304,0.0007738335,0.0006504054,0.001315581,0.001672711,0.001842845,0.004813251],"category_scores_gemma":[0.001981627,0.001024246,0.001789366,0.0006002923,0.001452959,0.001202755,0.0005241178,0.003553735,0.001560059],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001347799,"about_ca_system_score_gemma":0.004065935,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001275268,"about_ca_topic_score_gemma":0.003065073,"domain_scores_codex":[0.9989063,0.0005757514,0.00005997813,0.0001556166,0.0001193182,0.0001830208],"domain_scores_gemma":[0.9986034,0.0001525912,0.0003337543,0.0001580586,0.0001212782,0.0006308848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.852008,0.08738773,0.003158089,0.0004124623,0.00090545,0.0001516756,0.0002452548,0.002041735,0.01530593,0.0002187521,0.002847182,0.03531758],"study_design_scores_gemma":[0.7681881,0.2262857,0.002483613,0.00001155372,0.0001547654,0.00009138689,0.00002106799,0.0009830405,0.000893553,0.000131967,0.0007370769,0.00001813512],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871119,0.0006221116,0.0009022312,0.0005322294,0.0001440048,0.008361773,0.001000917,0.0001634186,0.001161384],"genre_scores_gemma":[0.9696792,0.0010167,0.004891071,0.001176703,0.0002828689,0.01674619,0.003020922,0.0000578536,0.003128496],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004813251,"threshold_uncertainty_score":0.02205688,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09047700081868112,"score_gpt":0.4332743799697267,"score_spread":0.3427973791510456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}